ACS Applied Materials & Interfaces · 2023 · 37 citations · 38 references
PharmacyOncologyPharmaceuticsDrug DeliveryMolecular OncologyTargeted Drug DeliveryCancer Drug DeliveryCancer NanomedicineNanocarriers For TherapeuticsNanomedicineNucleic Acid DeliveryTargeted Cancer TherapyAnticancer Drug LoadingCancer NanotherapyDna NanocarriersDrug Delivery NanocarriersStructural StabilityTargetingTumor-targeted Drug DeliveryTumor-targeted Ligands
Antibody drug conjugates (ADCs) have shown promise to be the mainstream chemotherapeutics for advanced HER2-positive cancers, yet the issues of poor drug delivery efficiency, limited chemotherapeutic effects, severe immune responses, and drug resistance remain to be addressed before the clinical applications of ADCs. The DNA aptamer-guided drug conjugates (ApDCs) are receiving growing attention for specific tumors due to their excellent tumor affinity and low cost. Therefore, developing a multivalent ApDC nanomedicine by combining anti-HER2 aptamer (HApt), tetrahedral framework nucleic acid (tFNA), and deruxtecan (Dxd) together to form HApt-tFNA@Dxd might help to address these concerns. In this study, the HER2-targeted DNA aptamer modified DNA tetrahedron (HApt-tFNA) was employed as a system for drug delivery, and the adoption of tFNA could effectively enlarge the drug-loading rate compared to aptamer-guided ApDCs previously reported. Compared with free Dxd and tFNA@Dxd, HApt-tFNA@Dxd showed better structural stability, excellent targeted cytotoxicity to HER2-positive gastric cancer, and increased tissue aggregation ability in tumors. These features and superiorities make HApt-tFNA@Dxd a promising chemotherapeutic medicine for HER2-positive tumors. Our work developed a new targeting nanomedicine by combining DNA nanomaterials and chemotherapeutic agents, which represents a critical advance toward developing novel DNA-based nanomaterials and promoting their potential applications for HER2-positive cancer therapy.
38
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi, Cristina Saura, Toshinari Yamashita et al. · New England Journal of Medicine · 2019 · 2K citations · Full text
Medicine, Oncology, Pharmacology +17
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara, Yung‐Jue Bang, Satoru Iwasa et al. · New England Journal of Medicine · 2020 · 1.3K citations · Full text
Medicine, Oncology, Pharmacology +17